Which medications are most effective for acute migraine management? A recent study assessed which ones appeared to work best based on reported patient experience.
Multiple medications are available for the management of acute migraine headaches (MH). However, there is little information on which ones patients report are most effective in clinical practice. A recent study published in Neurology sought to determine which of the medications appeared to work best based on reported patient experience. In the slides below, find key results and conclusions for clinicians.
Researchers analyzed 10 842 795 migraine attack records obtained from an e-diary smartphone app, which recorded whether the treatment was helpful, somewhat helpful, unsure, or unhelpful. The effects of 25 medications commonly used for the acute management of MH among 7 classes were studied: triptans, opioids, acetaminophen, NSAIDs, ergots, antiemetics, and combination analgesics (acetaminophen/acetylsalicylic acid/caffeine).
Compared to ibuprofen, the classes with the highest effectiveness were:
Triptans: 5x more effective
Ergots: 3x more effective
Antiemetics: 2.5x more effective
Opioids, NSAIDs (other than ibuprofen), combination analgesics, and acetaminophen were found to be less effective than the above 3 classes.
The individual medications that were found to be most effective were 3 triptans: eletriptan, zolmitriptan, and sumatriptan.
The findings indicate that of the MH medications available when the study was performed, triptans followed by ergots and antiemetics were the most effective according to the self reports of participants and, barring contraindications, should be tried first before proceeding to other medications.
Although several medications provided benefits for the greatest number of participants, other participants reported responding to the other medications studied. Thus, we are still left with the issue of which medication an individual patient is most likely to respond to.
Because the study was based on information obtained from 2014 to 2020, it did not include 2 of the newest classes of medication now available for the management of migraines: calcitonin gene-related peptide receptor antagonists (gepants) or 5-HT1F receptor agonists (ditans). Further studies will be required to determine how their efficacy compares with those of the medications examined in the study.
An important issue that the study did not address was whether the effectiveness of each medication was the same for both MH with aura and without aura. As many headache specialists consider these 2 separate syndromes with possibly different etiologies, it would be helpful to know if the same treatments were as effective for both.